Susquehanna International Group, LLP Protalix Bio Therapeutics, Inc. Put Options Transaction History
Susquehanna International Group, LLP
- $568 Billion
- Q1 2025
Put Options
8 transactions
Others Institutions Holding PLX
# of Institutions
70Shares Held
8.27MCall Options Held
227KPut Options Held
54.5K-
Jim Simons Renaissance Technologies LLC | New York, Ny1.19MShares$1.66 Million0.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny963KShares$1.35 Million0.0% of portfolio
-
Northern Trust Corp Chicago, IL685KShares$958,6610.0% of portfolio
-
Marshall Wace, LLP London, X0615KShares$861,1190.0% of portfolio
-
Connor, Clark & Lunn Investment Management Ltd.483KShares$676,0250.01% of portfolio
About Protalix BioTherapeutics, Inc.
- Ticker PLX
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 49,753,400
- Market Cap $69.7M
- Description
- Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso fo...